NCT06374459 2026-04-20
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Washington University School of Medicine
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT04549207 2026-04-07
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Ottawa Hospital Research Institute
Phase 4 Active not recruiting
NCT03401060 2026-03-31
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT04067726 2026-03-31
TRIDENT
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03620019 2026-03-27
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02833610 2026-02-18
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Massachusetts General Hospital
Phase 2 Completed
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
NCT04586660 2025-10-01
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Amgen
Phase 4 Active not recruiting
NCT06513624 2025-07-25
ETC-159-02
National University Hospital, Singapore
Phase 1 Recruiting
NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting